Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

2014490 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 15, Issue 6, pp. 580-591

Field-Weighted Citation Impact: 34.30